CYBB and acute myeloid leukemia: Inhibition of this pathway using NOX2-knockdown AML cells resulted in less bone marrow senescence and improved survival when compared to mice engrafted with control cells, suggesting that interrupting this process in the early stages of disease may provide the most therapeutic benefit.